N/A Completed N=15 Diagnostic

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

Source: ClinicalTrials.gov NCT03496844 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2022

Primary outcomePrimary: True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy — 13; 7; 6 participants

Summary

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

Outcome Measures

Outcome	Result	p-value
PRIMARY True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy	13; 7; 6	—

Eligibility Criteria

Inclusion Criteria

Male
Be ≥ 18 years of age
Diagnosed with prostate cancer
Be willing and able to provide informed consent
Be informed of the investigational nature of this study

Exclusion Criteria

Having a history of severe claustrophobia
Weight exceeding 400lbs

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03496844). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.